Ocuphire Pharma (Ocuphire Pharma) FCF Margin % : 268.95% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Ocuphire Pharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Ocuphire Pharma's Free Cash Flow for the three months ended in Dec. 2023 was $4.55 Mil. Ocuphire Pharma's Revenue for the three months ended in Dec. 2023 was $1.69 Mil. Therefore, Ocuphire Pharma's FCF Margin % for the quarter that ended in Dec. 2023 was 268.95%.

As of today, Ocuphire Pharma's current FCF Yield % is -2.12%.

The historical rank and industry rank for Ocuphire Pharma's FCF Margin % or its related term are showing as below:

OCUP' s FCF Margin % Range Over the Past 10 Years
Min: -3288.62 Med: -5.84 Max: 35.92
Current: -5.84

During the past 5 years, the highest FCF Margin % of Ocuphire Pharma was 35.92%. The lowest was -3288.62%. And the median was -5.84%.

OCUP's FCF Margin % is ranked better than
75.41% of 1037 companies
in the Biotechnology industry
Industry Median: -147.18 vs OCUP: -5.84

Ocuphire Pharma FCF Margin % Historical Data

The historical data trend for Ocuphire Pharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocuphire Pharma FCF Margin % Chart

Ocuphire Pharma Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-3,288.62

35.92

-5.84

Ocuphire Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial												72.25	-208.46	26.92	-25.16	268.95

Competitive Comparison of Ocuphire Pharma's FCF Margin %

For the Biotechnology subindustry, Ocuphire Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ocuphire Pharma's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocuphire Pharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Ocuphire Pharma's FCF Margin % falls into.

Ocuphire Pharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Ocuphire Pharma's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-1.112	/	19.049
	=	-5.84 %

Ocuphire Pharma's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	4.548	/	1.691
	=	268.95 %

Ocuphire Pharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of Ocuphire Pharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocuphire Pharma (Ocuphire Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocuphire Pharma Inc (NAS:OCUP) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

R3X1:Germany

Address

37000 Grand River Avenue, Suite 120, Farmington Hills, MI, USA, 48335

Website

https://www.ocuphire.com

Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.

Executives

George Magrath	officer: Chief Executive Officer	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Ronil A. Patel	officer: SVP, Operations & Bus. Dev.	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Mina Sooch	director, officer: President and CEO	17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Manuso James S J	director	5130 ROUTE 212, WILLOW NY 12495
Jay Pepose	director	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Susan Benton	director	3916 VALRICO GROVE DRIVE, VALRICO FL 33594
Rabourn Amy Zaremba	officer: VP of Finance	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Cam Gallagher	director	6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121
Alan R Meyer	director
Sean Ainsworth	director	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Bernhard Hoffmann	officer: VP of Corp. Dev. & Ops & Sec.	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Lara Sullivan	director	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
Ben Gil Price	director	8297 CHAMPIONS GATE BLVD. #444, CHAMPIONS GATE FL 33896
Douglas J Swirsky	officer: President and CFO	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Lisa Nolan	officer: Chief Business Officer	36 ROCKLAND MILLS, ROCKLAND DE 19732